MarketPulse
A

$ALLR

3 articles found
3 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

PARP Inhibitor Pipeline Surges: 25+ Pharma Giants Race to Expand Cancer Drug Arsenal

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.
AZNGILDALLRclinical trialscancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Allarity Therapeutics

Allarity Therapeutics Secures Patent Allowance for Stenoparib Companion Diagnostic

Allarity Therapeutics received USPTO notice of allowance for stenoparib DRP® companion diagnostic patent, providing exclusivity through 2039.
ALLRPhase 2 clinical trialstenoparib
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allarity Therapeutics Secures $20M Funding to Accelerate Stenoparib FDA Path

Allarity Therapeutics secures $20M non-dilutive debt financing to complete stenoparib Phase 2 trial and advance toward FDA approval, extending runway to mid-2028.
ALLRFDA approvaldebt financing